, Health and Social Care Committee
Gynaecological cancers: Panel 2
That's fine. Thank you, Dr Louise. Professor Tom, can you hear me, and can we hear you?
, Health and Social Care Committee
Gynaecological cancers: Panel 2
The question is, I suppose, whether not having the kind of facilities available that might be available elsewhere in the UK means there's an issue in terms of attracting colleagues to come and work in Wales.
, Health and Social Care Committee
Gynaecological cancers: Panel 2
Attracting people, yes, but attracting specialists in the first place to come and work in Wales.
, Health and Social Care Committee
Gynaecological cancers: Panel 2
I suppose one of the points of the question was whether we have the expertise and technologies and the facilities in Wales to attract the kind of world-class specialists that we need.
, Health and Social Care Committee
Gynaecological cancers: Panel 2
Okay. It could be that some members want to come in with some more specifics following that answer, Dr Louise. I'll come back to you in a moment. I'll give you advance notice. I'll come back to Professor Tom Crosby in a moment, but I'll give you advance…
, Health and Social Care Committee
Gynaecological cancers: Panel 2
I suppose, as a general opening question, recognising that variation, is it ever possible to make sure that we have equality across Wales, or is that perhaps unrealistic? Is it a case of depending on where you live and what your circumstances are?
, Health and Social Care Committee
Gynaecological cancers: Panel 2
Thank you ever so much for being with us. I suppose one question is: do you think that there's equity of access to diagnostics and treatment in regard to gynaecological cancers across Wales? Do you think there's an issue of equality depending on where people…
, Health and Social Care Committee
Gynaecological cancers: Panel 2
Welcome back to the Health and Social Care Committee. We move to item 7 in regard to our inquiry on gynaecological cancers, and we've got oral evidence. We've had two earlier sessions today, and this is our third and last panel of today. I would like to…
, Health and Social Care Committee
Gynaecological cancers: Panel 1
You're happy that you've told us everything you need to help us in terms of this inquiry. Thank you for that. This is the second session, so we've got more sessions to come, but, by all means, if you do have a chance to watch them and you think of anything…
, Health and Social Care Committee
Gynaecological cancers: Panel 1
Thank you, Sarah. We're out of time, but if there's anything crucial that you think we've not asked you about, or that you've not had an opportunity to say something, or if we've missed something, then, by all means, just indicate now. No.
, Health and Social Care Committee
Gynaecological cancers: Panel 1
That was to Richard, I think. Did you hear that question all right, Richard?
, Health and Social Care Committee
Gynaecological cancers: Panel 1
Dr Aarti.
, Health and Social Care Committee
Gynaecological cancers: Panel 1
We can resume this line of questioning on 14 June. Thank you. We're a little bit short of time, but, Sarah Murphy, did you want to come back in on some final questions?
, Health and Social Care Committee
Gynaecological cancers: Panel 1
Sarah.
, Health and Social Care Committee
Gynaecological cancers: Panel 1
I can see Richard wants to come in, but I've just been reminded as well that we've got the All Wales Medicines Strategy Group coming in to give evidence on 14 June, so that will help us in this regard. Richard, did you want to come in?
, Health and Social Care Committee
Gynaecological cancers: Panel 1
Okay. Jack.
, Health and Social Care Committee
Gynaecological cancers: Panel 1
Are there drugs in Wales that are available that are not available in other parts of the UK?
, Health and Social Care Committee
Gynaecological cancers: Panel 1
Okay. I think it's something that as a committee we need to understand in terms of the—. Because the NICE guidance is UK wide and is adopted by all four of the NHS bodies across the UK, but then it's the funding arrangements that sit under that that are…
, Health and Social Care Committee
Gynaecological cancers: Panel 1
That's right.
, Health and Social Care Committee
Gynaecological cancers: Panel 1
Is there a different process? Can you explain the different process between England and Wales in terms of the process that has to be gone through to have a drug approved?
, Health and Social Care Committee
Gynaecological cancers: Panel 1
Yes. I know WHSSC, yes.
, Health and Social Care Committee
Gynaecological cancers: Panel 1
An equality issue, further, as well. Did you want to come in on this question at all, Richard?
, Health and Social Care Committee
Gynaecological cancers: Panel 1
Yes. It's not for our committee to try and work out what the Government's response would be, but I'm just trying to understand the Government's response, if they've got priorities in other areas and they're focusing on something else. That, no doubt, will be…
, Health and Social Care Committee
Gynaecological cancers: Panel 1
Her response.
, Health and Social Care Committee
Gynaecological cancers: Panel 1
I know. I've got cases of that happening myself.
